Clinical candidate and genistein analogue AXP107‐11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein‐coupled estrogen receptor signaling

Despite advances in cancer therapeutics, pancreatic cancer remains difficult to treat and often develops resistance to chemotherapies. We have evaluated a bioavailable genistein analogue, AXP107‐11 which has completed phase Ib clinical trial, as an approach to sensitize tumor cells to chemotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Mesmar, Fahmi, Dai, Bingbing, Ibrahim, Ahmed, Hases, Linnea, Jafferali, Mohammed Hakim, Jose Augustine, Jithesh, DiLorenzo, Sebastian, Kang, Ya'an, Zhao, Yang, Wang, Jing, Kim, Michael, Lin, Chin‐Yo, Berkenstam, Anders, Fleming, Jason, Williams, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912054/
https://www.ncbi.nlm.nih.gov/pubmed/31568691
http://dx.doi.org/10.1002/cam4.2581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912054/
https://www.ncbi.nlm.nih.gov/pubmed/31568691
http://dx.doi.org/10.1002/cam4.2581

Ejemplares similares